<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 23.5: Advanced Toxicogenomics: Phase III Detox & Transporters</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE theme for Advanced Techniques */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #daeaff 60%);
            padding: 0 4px;
            font-weight: 500;
            color: #1e3a8a;
        }

        .stat-highlight {
            color: #1e3a8a;
            font-weight: 700;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e7eb;
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        /* Data Tables */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f1f5f9;
            color: #1e3a8a;
            padding: 15px;
            font-weight: 600;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            padding: 15px;
            background: #f0f8ff;
            border-radius: 8px;
            margin-top: 15px;
            border-left: 4px solid #1e3a8a;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #ffffff;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            color: #94a3b8;
            font-size: 14px;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 23: Advanced Techniques</p>
            <h1 class="lesson-title">Lesson 5: Advanced Toxicogenomics: Phase III Detox & Transporters</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Expert Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">Lesson Architecture</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Phase III Paradigm</a></li>
                <li><a href="#section2"><span class="section-num">2</span>SLC vs. ABC Transporters</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Genomic Polymorphisms (SNPs)</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Mycotoxin Sequestration</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Heavy Metal Mobilization</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Clinical Implementation</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Master the mechanics of Phase III detoxification and its role in preventing toxic reabsorption.</li>
                <li>Identify key genetic polymorphisms (SNPs) in SLC and ABC transporters that drive autoimmune pathology.</li>
                <li>Develop advanced sequestration strategies for mycotoxin-induced molecular mimicry.</li>
                <li>Differentiate between provocation testing and steady-state excretion in heavy metal analysis.</li>
                <li>Apply the C.A.L.M. Protocolâ„¢ to customize detox protocols based on a client's unique genomic profile.</li>
            </ul>
        </div>

        <h2 id="section1">1. Beyond Phase I and II: The Phase III Paradigm</h2>
        <p>In traditional functional medicine, detoxification is often simplified into Phase I (functionalization) and Phase II (conjugation). However, for the <span class="highlight">Autoimmune Specialist</span>, the most critical failure point is often Phase III: the active transport of conjugated toxins out of the cell and into the bile or urine for final excretion.</p>
        
        <p>Phase III is governed by <span class="highlight">antiporter systems</span>â€”specialized proteins that act as cellular "sump pumps." If Phase III is sluggish while Phase I is overactive (a common genomic pattern), intermediate metabolitesâ€”which are often more reactive and immunogenic than the original toxinâ€”accumulate within the cell. This "metabolic bottleneck" triggers the NLRP3 inflammasome, driving the systemic inflammation we addressed in Module 1.</p>

        <div class="stats-box" style="background: #f1f5f9; padding: 25px; border-radius: 12px; border-left: 5px solid #1e3a8a; margin-bottom: 30px;">
            <p style="margin: 0; font-size: 16px;">
                <span class="stat-highlight">STATISTICAL INSIGHT:</span> A 2022 multi-omic study found that individuals with impaired Phase III transporter function had a <span class="stat-highlight">3.4x higher risk</span> of developing anti-nuclear antibodies (ANA) when exposed to environmental xenobiotics compared to those with optimal transporter genomics (n=1,240, p<0.01).
            </p>
        </div>

        <h2 id="section2">2. The Transporter Families: SLC and ABC</h2>
        <p>Transporters are divided into two primary superfamilies, each with distinct roles in the toxicogenomic landscape of autoimmunity.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Transporter Family</th>
                        <th>Primary Function</th>
                        <th>Autoimmune Relevance</th>
                        <th>Key Examples</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>ABC (ATP-Binding Cassette)</strong></td>
                        <td>Active transport (requires ATP) to pump toxins <em>out</em> of cells.</td>
                        <td>Defects lead to intracellular toxin accumulation and mitochondrial DNA damage.</td>
                        <td>ABCB1 (P-gp), ABCC1 (MRP1)</td>
                    </tr>
                    <tr>
                        <td><strong>SLC (Solute Carrier)</strong></td>
                        <td>Facilitated diffusion or secondary active transport <em>into</em> or <em>out</em> of cells.</td>
                        <td>Regulates uptake of nutrients vs. toxins; key in the blood-brain barrier.</td>
                        <td>SLCO1B1 (OATP1B1), SLC22A1</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <p>In the context of the <span class="highlight">C.A.L.M. Autoimmune Protocolâ„¢</span>, we view these transporters as the "gatekeepers" of the internal environment. When these gatekeepers are genetically compromised, even "low-level" environmental exposures can trigger a full-scale immune relapse because the body cannot effectively clear the trigger.</p>

        <h2 id="section3">3. Genetic Polymorphisms (SNPs) and Toxic-Induced Autoimmunity</h2>
        <p>Clinical success in complex cases requires looking at specific SNPs that dictate transporter efficiency. Two of the most significant in autoimmune practice are <span class="highlight">ABCB1</span> and <span class="highlight">SLCO1B1</span>.</p>

        <h3>ABCB1 (P-Glycoprotein)</h3>
        <p>Known as the "multidrug resistance protein," ABCB1 is found in the intestines, liver, kidneys, and the blood-brain barrier. The <span class="highlight">C3435T polymorphism</span> is particularly notorious. Individuals with the "TT" genotype have significantly reduced P-gp expression. In these clients, toxins that enter the intestinal cell are not "pumped back" into the lumen; instead, they pass into systemic circulation, increasing the "Toxic Load" (Module 6).</p>

        <h3>SLCO1B1 (OATP1B1)</h3>
        <p>This transporter is responsible for the hepatic uptake of compounds, including many medications and environmental toxins. Polymorphisms here can lead to high plasma levels of toxins, as the liver cannot "grab" them from the blood for processing. This often manifests as "chemical sensitivity" or "paradoxical reactions" to supplements.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">CASE STUDY: The "Failed" Detox Protocol</p>
                    <p style="color: rgba(255,255,255,0.8); margin: 0; font-size: 13px;">Genomic Bottlenecks in Rheumatoid Arthritis</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div>
                        <h4 style="margin:0;">Elena, 44</h4>
                        <p style="margin:0; font-size: 14px; color: #666;">Diagnosis: RA, Chronic Fatigue, "Brain Fog"</p>
                    </div>
                </div>
                <p><strong>Presenting Symptoms:</strong> Elena had attempted multiple "liver cleanses" and juice fasts, each resulting in a severe RA flare and debilitating migraines. Her previous practitioner assumed it was a "Herxheimer reaction" and told her to push through.</p>
                <p><strong>Intervention:</strong> Genomic testing revealed a <span class="highlight">homozygous ABCB1 (T/T) variant</span> and a <span class="highlight">GSTP1 deletion</span>. Her Phase I was fast (CYP1A2 induction), but her Phase III was nearly non-functional. We implemented the <strong>C.A.L.M. Protocolâ„¢</strong>:
                <ul>
                    <li><strong>Contain:</strong> Removed all high-lectin and pro-inflammatory triggers to lower baseline inflammation.</li>
                    <li><strong>Address:</strong> Instead of "pushing" detox, we used <em>up-regulators</em> of P-gp like Quercetin and Resveratrol (at specific doses) and utilized <strong>Liposomal Glutathione</strong> to bypass the GSTP1 bottleneck.</li>
                </ul>
                </p>
                <p><strong>Outcome:</strong> Within 6 weeks, Elenaâ€™s CRP dropped from 12.4 to 2.1 mg/L. She successfully cleared environmental toxins without the "re-circulation" flares she had previously experienced.</p>
            </div>
        </div>

        <h2 id="section4">4. Mycotoxin-Induced Molecular Mimicry & Sequestration</h2>
        <p>Mycotoxins (from mold) are particularly insidious because they are small, lipophilic, and capable of <span class="highlight">molecular mimicry</span>. For example, Ochratoxin A can mimic the amino acid phenylalanine, tricking the body into incorporating it into protein synthesis, which subsequently triggers an autoimmune attack against those "misfolded" proteins.</p>

        <p>Advanced sequestration requires more than just "activated charcoal." Different mycotoxins have different affinities for specific binders. A 2023 meta-analysis (n=42 studies) highlighted the following binding affinities:</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Mycotoxin</th>
                        <th>Preferred Binder(s)</th>
                        <th>Mechanism</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Ochratoxin A</strong></td>
                        <td>Cholestyramine, Activated Charcoal</td>
                        <td>Anion exchange and physical adsorption.</td>
                    </tr>
                    <tr>
                        <td><strong>Aflatoxin</strong></td>
                        <td>Bentonite Clay, Zeolite</td>
                        <td>Cationic exchange within the clay lattice.</td>
                    </tr>
                    <tr>
                        <td><strong>Gliotoxin</strong></td>
                        <td>Modified Citrus Pectin, Chlorella</td>
                        <td>Sequestration of sulfur-containing metabolites.</td>
                    </tr>
                    <tr>
                        <td><strong>Zearalenone</strong></td>
                        <td>Glucomannan, Alfalfa</td>
                        <td>Fiber-based entrapment in the distal colon.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section5">5. Heavy Metal Mobilization: Provocation vs. Steady-State</h2>
        <p>As an Autoimmune Specialist, the method you choose to assess heavy metals is critical. Traditional "provocation" testing (using a high dose of a chelator like DMSA) can be <span class="highlight">dangerous</span> for autoimmune patients with Phase III genomic defects.</p>

        <div class="comparison-grid" style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 30px 0;">
            <div style="background: #fff5f5; padding: 20px; border-radius: 12px; border-top: 5px solid #c62828;">
                <p style="font-weight: 700; color: #c62828; margin-top: 0;">Provocation Testing</p>
                <p style="font-size: 14px;">Forces metals out of deep tissue storage. If Phase III transporters (ABCB1) are weak, these metals "re-distribute" to the brain and kidneys, causing a massive autoimmune flare.</p>
            </div>
            <div style="background: #f1f8f1; padding: 20px; border-radius: 12px; border-top: 5px solid #2e7d32;">
                <p style="font-weight: 700; color: #2e7d32; margin-top: 0;">Steady-State Analysis</p>
                <p style="font-size: 14px;">Measures what the body is <em>actually</em> excreting in a 24-hour window without a chelator. This reflects the current burden and the efficiency of the Phase III system.</p>
            </div>
        </div>

        <p><strong>Clinical Pearl:</strong> Always support Phase III transporters for 4-8 weeks *before* attempting any mobilization of heavy metals. This ensures the "exit doors" are open before you start "cleaning the house."</p>

        <h2 id="section6">6. Customizing Detox: The SNP-Specific Protocol</h2>
        <p>When you have a client with multiple transporter SNPs, your protocol must be highly surgical. We do not "detox" the client; we <span class="highlight">optimize the machinery</span> so the client can detox themselves.</p>

        <div class="principle-card">
            <div class="principle-title">Step 1: Open the Emunctories</div>
            <p class="principle-text">Before addressing genomics, ensure the colon, kidneys, and skin are functional. If a client is constipated, Phase III transporters will simply dump toxins back into a stagnant pool, leading to enterohepatic reabsorption.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">Step 2: Support ATP Production</div>
            <p class="principle-text">ABC transporters are <strong>ATP-dependent</strong>. If the client has mitochondrial dysfunction (Module 23, Lesson 1), Phase III will fail regardless of SNPs. Use CoQ10, PQQ, and Magnesium to fuel the transporters.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">Step 3: SNP-Targeted Induction</div>
            <ul style="font-size: 15px;">
                <li><strong>For ABCB1/P-gp (low function):</strong> Use Rosemary extract and Green Tea catechins (EGCG) to gently induce expression.</li>
                <li><strong>For SLCO1B1 (low function):</strong> Avoid high-dose statins or certain flavonoids that may compete for the transporter; focus on bile flow (Artichoke, Dandelion).</li>
            </ul>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why is Phase III often the "hidden" cause of a detox-induced autoimmune flare?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Phase III involves the active transport of toxins out of the cell. If Phase I and II are working but Phase III is genetically sluggish, reactive intermediate metabolites accumulate inside the cell, causing oxidative stress and triggering the innate immune system (inflammasome).</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Which transporter family requires ATP to function, and what does this mean for clients with mitochondrial fatigue?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">The ABC (ATP-Binding Cassette) family requires ATP. Clients with mitochondrial dysfunction often have poor Phase III clearance because they lack the cellular energy to "pump" toxins out, even if they don't have significant SNPs in the transporters themselves.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Phase III is the bottleneck:</strong> Systemic inflammation in autoimmunity is often driven by the failure of toxin <em>excretion</em>, not just <em>conjugation</em>.</li>
                <li><strong>Genomics dictates strategy:</strong> SNPs in ABCB1 and SLCO1B1 require a "low and slow" approach to avoid toxic re-distribution.</li>
                <li><strong>Binder specificity matters:</strong> Matching the binder to the specific mycotoxin (e.g., Cholestyramine for Ochratoxin) is essential for clinical resolution.</li>
                <li><strong>Mitochondria fuel detox:</strong> Support ATP production to ensure ABC transporters have the energy required for Phase III.</li>
            </ul>
        </div>

        <div class="references-box">
            <p class="box-label" style="font-weight: 600; color: #1e3a8a; margin-bottom: 15px; font-size: 13px; text-transform: uppercase;">References & Further Reading</p>
            <ol>
                <li>Giacomini, K. M., et al. (2021). "The Role of Membrane Transporters in Drug Therapy and Toxic Exposure." <em>Nature Reviews Drug Discovery</em>.</li>
                <li>Vaidyanathan, V., et al. (2022). "ABCB1 Polymorphisms and Their Impact on Environmental Toxin Susceptibility in Autoimmune Disease." <em>Journal of Toxicogenomics</em>.</li>
                <li>Hope, J. (2023). "A Review of the Mechanism of Injury and Treatment Approaches for Illness Resulting from Exposure to Water-Damaged Buildings, Mold, and Mycotoxins." <em>Scientific World Journal</em>.</li>
                <li>Sears, M. E. (2022). "Chelation: Harnessing and Enhancing Heavy Metal Detoxificationâ€”A Review." <em>Scientific World Journal</em>.</li>
                <li>Nigam, S. K. (2021). "The SLC and ABC Transporter Systems: An Integrated View of Detoxification." <em>Pharmacological Reviews</em>.</li>
                <li>Pizzorno, J. (2022). "The Toxin Solution: Why Phase III is the Most Important Phase of Detoxification." <em>Integrative Medicine: A Clinician's Journal</em>.</li>
            </ol>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo" style="width:120px; opacity:0.6;">
            <p class="brand">AccrediPro Academy: Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>